Obeticholic Acid (Synonyms: INT 747, Obeticholic Acid) |
| Catalog No.GC14158 |
L'acide obéticholique (INT-747) est un agoniste FXR puissant, sélectif et actif par voie orale avec une EC50 de 99 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 459789-99-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Obeticholic Acid (INT-747; 6-ECDCA; 6-Ethylchenodeoxycholic acid) is a potent, selective and orally active farnesoid X receptor(FXR) agonist with an EC50 of 99nM[1]. FXR is a ligand-dependent transcription factor belonging to the nuclear hormone receptor superfamily that plays an important role in bile acid, lipid metabolism, carbohydrate homeostasis and inflammatory response[2]. Obeticholic Acid is a semisynthetic hydrophobic bile acid analog used to treat primary biliary cholangitis(PBC) and non-alcoholic steatohepatitis(NASH)[3].
In vitro, treatment of HepG2, Huh7 and SNU-449 cells with Obeticholic Acid (0.01-100µM) for 72h significantly inhibited cell proliferation with IC50 values of 1.067μM, 1.038μM and 0.706μM, respectively, and also inhibited cell migration and invasion[4]. Treatment of primary cultures of human intrahepatic cholangiocarcinoma(iCCA) with Obeticholic Acid (0-2.5µM) for 3-10 days significantly inhibited the proliferation of mucinous and mixed iCCA cells and upregulated FXR gene expression[5].
In vivo, oral treatment of mice with NASH with Obeticholic Acid (10mg/kg) for 4 or 8 weeks significantly inhibited the number of hepatic coronary structures(hCLS), reduced the area of fibrosis and the mRNA expression of fibrotic genes, and long-term treatment had no effect on the body weight and adipose tissue weight of mice[6]. Oral treatment of rats with ascites cirrhosis with Obeticholic Acid (5mg/kg) for 2 weeks significantly reduced intestinal bacterial translocation, reduced intestinal immune cell infiltration, and normalized the expression of inflammatory cytokines[7].
References:
[1] Pellicciari R, Fiorucci S, Camaioni E, et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity[J]. Journal of medicinal chemistry, 2002, 45(17): 3569-3572.
[2] Shaik F B, Prasad D V R, Narala V R. Role of farnesoid X receptor in inflammation and resolution[J]. Inflammation Research, 2015, 64: 9-20.
[3] Chapman R W, Lynch K D. Obeticholic acid—a new therapy in PBC and NASH[J]. British medical bulletin, 2020, 133(1): 95-104.
[4] Attia Y M, Tawfiq R A, Ali A A, et al. The FXR agonist, obeticholic acid, suppresses HCC proliferation & metastasis: role of IL-6/STAT3 signalling pathway[J]. Scientific reports, 2017, 7(1): 12502.
[5] Di Matteo S, Nevi L, Costantini D, et al. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma[J]. PLoS One, 2019, 14(1): e0210077.
[6] Goto T, Itoh M, Suganami T, et al. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis[J]. Scientific reports, 2018, 8(1): 8157.
[7] Úbeda M, Lario M, Muñoz L, et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats[J]. Journal of hepatology, 2016, 64(5): 1049-1057.
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *